Navigation Links
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
Date:9/2/2008

- First of three ongoing randomized chemotherapy combination trials to

evaluate HGS-ETR1 in the treatment of specific cancers -

ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination vs. bortezomib alone.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We continue to be excited about HGS-ETR1 and our TRAIL receptor antibody program," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "The TRAIL-mediated apoptosis pathway is an important area of cancer research, and agonistic antibodies to this target offer great promise. HGS-ETR1 is the most advanced of any product in development that targets this pathway, with three randomized chemotherapy combination trials currently ongoing to evaluate its potential for the treatment of specific cancers. We look forward to maturing results from all three trials. Taken together, these results will inform our decision on whether to advance HGS- ETR1 to Phase 3 development."

Key Findings

The trial in advanced multiple myeloma is a randomized, multi-center, open-label Phase 2 study to evaluate the efficacy and safety of HGS-ETR1 (mapatumumab) in combination with bortezomib in these patients. 104 patients are being treat
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The clinical and medical insights provided by ... a product,s success or failure. Despite this, many biopharmaceutical ... – and then to coordinate activities and outreach over ... which successful KOL engagement rests. According ... inconsistencies in their KOL management systems and are working ...
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... 2014 Research and Markets has ... Therapeutics Market & Pipeline Insight 2014" report to ... to prevent and eradicate the prevalence of cancer have ... confined to low specificity, safety and large number of ... a better solution. It has been discovered that peptides ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... 8, 2011 Smith & Nephew (NYSE: ... its innovative, single-use DYONICS PLATINUM Series Shaver Blades which ... The removal of tissue, cartilage and bone ... The more precise and efficient surgeons are with their ...
... Sept. 8, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0611073/Global-Intravascular-Ultrasound-IVUS-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_I This report ... (IVUS) in US$ Million by the following ...
Cached Medicine Technology:Smith & Nephew's New DYONICS™ PLATINUM Series Shaver Blades Establish New Standard for Leading-edge Resection Performance 2Smith & Nephew's New DYONICS™ PLATINUM Series Shaver Blades Establish New Standard for Leading-edge Resection Performance 3Smith & Nephew's New DYONICS™ PLATINUM Series Shaver Blades Establish New Standard for Leading-edge Resection Performance 4Global Intravascular Ultrasound (IVUS) Industry 2Global Intravascular Ultrasound (IVUS) Industry 3Global Intravascular Ultrasound (IVUS) Industry 4Global Intravascular Ultrasound (IVUS) Industry 5Global Intravascular Ultrasound (IVUS) Industry 6Global Intravascular Ultrasound (IVUS) Industry 7Global Intravascular Ultrasound (IVUS) Industry 8Global Intravascular Ultrasound (IVUS) Industry 9Global Intravascular Ultrasound (IVUS) Industry 10Global Intravascular Ultrasound (IVUS) Industry 11Global Intravascular Ultrasound (IVUS) Industry 12Global Intravascular Ultrasound (IVUS) Industry 13
(Date:8/30/2014)... Seattle, WA (PRWEB) August 30, 2014 One ... of this era is the gluten-free diet. Originally meant for ... has become a catchall for people who are looking to ... gluten. However, not only is this kind of information erroneous, ... of health problems because of a drastic change in ...
(Date:8/30/2014)... August 30, 2014 August 28th, 2014: ... pain in our society and the toll that takes ... it’s vital that continuing education for physical therapists addresses ... help physical therapists help others, Hands-On Seminars is offering ... , Three learning styles are available to fit ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 When a prominent ... ensue, as happened on Wednesday, August 27th, when news began ... on JPMorgan Chase & Co and at least one ... is actually investigating attacks on seven prominent banks , ... may be affected, and the buzz quickly goes viral. ...
(Date:8/30/2014)... August 30, 2014 As 500 Zoloft lawsuits ... when give to pregnant mothers, Wright & Schulte LLC recently ... M. Rufe. The remand in the Zoloft lawsuits ... 18 states and are involved in one SSRI lawsuit ... have their Zoloft birth defect lawsuit sent back to the ...
(Date:8/30/2014)... August 30, 2014 Barton Associates, an ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... Austin, TX; and Jupiter, FL. , Barton Associates made ... the physician shortage crisis affecting the United States, a ...
Breaking Medicine News(10 mins):Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates to Open a New Office Location in Keene, NH 2
... Colonic lipomas have been found in related literature. One ... 14 issue of the World Journal of Gastroenterology because ... discussed age and sex factors, clinical and histopathological findings, ... and previously available literature. , The article reported ...
... Food and Drug Administration (FDA) has awarded the ... $1 million Orphan Products Development grant to study ... skin or internal organs., The unique, interdisciplinary, and ... Drolet, M.D., professor of dermatology and pediatrics, at ...
... Researchers at the Board of Governors Gene Therapeutics Research ... first time that it is possible to sustain therapeutic ... to a year, even in the presence of an ... humans. , The researchers demonstrated in an animal ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... long-term outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... peptide (ANP) can lessen cardiac injuries after heart attack and ... a Japanese study in this week,s issue of The ... damaged heart muscle (infarct) and lessened what,s known as "reperfusion ...
... 26 AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Inc Webcast, When: November 1, 2007 @ 8:30 AM ... over the Internet -- Simply log on to the web at ... Contact: Lisa Gould of AMICAS, Inc, 617-779-7892. If you ...
Cached Medicine News:Health News:The largest colonic lipoma to date 2Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2
... The ACMI USA Series ACN-2 Flexible ... procedures. It is ideal for office practice. ... channel accommodates a full range of operating ... small outer diameter, and beveled, UltraGlide covered ...
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
... Instrument System is a small power instrument ... modular and unitized handpieces., ,Electric Motor ... 1025 Power Console. Accepts all 1000 and ... hand throttle (#1000E) for use with foot ...
... Electric Micro Sagittal Saw, with ... deg. arc. Head rotates 360 ... angle, and our unique blade ... Can also be purchased without ...
Medicine Products: